Interleukin-12 induces sustained activation of multiple host inflammatory mediator systems in chimpanzees

Journal of Infectious Diseases

Volumn 179, Issue 3, 1999, Pages 646-652

  Lauw, Fanny N ^a,b,c   Dekkers, Pascale E P ^a,b   Te Velde, Anje A ^a,b   Speelman, Peter ^a,b   Levi, Marcel ^a,b   Kurimoto, Masashi ^a,b   Hack, C Erik ^a,b   Van Deventer, Sander J H ^a,b   Van Der Poll, Tom ^a,b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b HAYASHIBARA BIOCHEMICAL LABORATORIES INC   (Japan)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; LEUKOCYTE ELASTASE; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; RECOMBINANT INTERLEUKIN 12; THROMBIN ANTITHROMBIN COMPLEX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHIMPANZEE; CONTROLLED STUDY; DEGRANULATION; IMMUNOPATHOGENESIS; IMMUNOREGULATION; INFLAMMATION; LEUKOCYTE ACTIVATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEPSIS;

ANIMALS; BLOOD COAGULATION FACTORS; CHEMOKINE CCL2; CHEMOKINES; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBRINOLYSIS; HUMANS; INFLAMMATION; INJECTIONS, INTRAVENOUS; INTERFERON TYPE II; INTERLEUKIN-12; INTERLEUKIN-15; INTERLEUKIN-18; MACROPHAGE INFLAMMATORY PROTEIN-1; NEUTROPHILS; PAN TROGLODYTES; RECOMBINANT PROTEINS; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0033397699     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314636     Document Type: Article

References (43)

1. 1. Trinchieri G. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994; 84:4008-27.
2. 2. Seder RA, Kelsall BL, Jankovic D. Differential roles for IL-12 in the maintenance of immune responses in infectious versus autoimmune disease. J Immunol 1996; 157:2745-8.
3. 3. Heinzel FP, Rerko RM, Ling P, Hakimi J, Schoenhaut DS. Interleukin 12 is produced in vivo during endotoxemia and stimulates synthesis of gamma interferon. Infect Immun 1994; 62:4244-9.
4. 4. Jansen PM, van der Pouw Kraan TCTM, de Jong IW, et al. Release of interleukin-12 in experimental Escherichia coli septic shock in baboons: relation to plasma levels of interleukin-10 and interferon-γ. Blood 1996; 87:5144-51.
5. 5. Hazelzet JA, Kornelisse RF, van der Pouw Kraan TCTM, et al. Interleukin 12 levels during the initial phase of septic shock with purpura in children. Relation to severity of disease. Cytokine 1997; 9:711-6.
6. 6. Van der Poll T, Jansen PM, Montegut WJ, et al. Effects of IL-10 on systemic inflammatory responses during sublethal primate endotoxemia. J Immunol 1997; 158:1971-5.
7. 7. Wysocka M, Kubin M, Vieira LQ, et al. Interleukin-12 is required for interferon-γ production and lethality in lipopolysaccharide-induced shock in mice. Eur J Immunol 1995; 25:672-6
8. 8. Glauser MP, Heumann D, Baumgartner JD, Cohen J. Pathogenesis and potential strategies for prevention and treatment of septic shock: an update. Clin Infect Dis 1994; 18:S205-16.
9. 9. Levi M, ten Cate H, van der Poll T, van Deventer SJH. New insights in the pathogenesis of disseminated intravascular coagulation in sepsis. JAMA 1993; 270:975-9.
10. 10. Leonard JP, Sherman ML, Fisher GL, et al. Effects of single-dose interleukin-12 exposure on interleukin-12 associated toxicity and interferon-γ production. Blood 1997; 90:2541-8.
11. 11. van Leenen D, van der Poll T, Levi M, et al. Pentoxifylline attenuates neutrophil activation in experimental endotoxemia in chimpanzees. J Immunol 1993; 151:2318-25.
12. 12. Levi M, ten Cate H, Bauer KA, et al. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti tissue factor antibody in chimpanzees. J Clin Invest 1994; 93: 114-20.
13. 13. Taniguchi M, Nagaoka K, Kunikata T, et al. Characterization of anti human interleukin-18 (IL-18)/interferon-γ inducing factor (IGIF) monoclonal antibodies and their application in the measurement of human IL-18 by ELISA. J Immunol Methods 1997; 206:107-13.
14. 14. van der Poll T, Jansen J, van Leenen D, et al. Release of soluble receptors for tumor necrosis factor in clinical sepsis and experimental endotoxemia. J Infect Dis 1993; 168:955-60.
15. 1-antitrypsin and lactoferrin in sepsis: evidence for neutrophils as mediators in fatal sepsis. J Lab Clin Med 1992; 119:159-68.
16. 16. van der Poll T, Levi M, van Deventer SJH, et al. Differential effects of anti tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees. Blood 1994; 83:446-51.
17. 17. Pajkrt D, van der Poll T, van Deventer SJH. Inflammatory responses during human endotoxemia. In: Vincent JL, ed. Yearbook of intensive care and emergency medicine. Springer-Verlag, 1997:14-30.
18. 18. van der Poll T, Coyle SM, Levi M, et al. Effect of a recombinant dimeric tumor necrosis factor receptor on inflammatory responses to intravenous endotoxin in normal humans. Blood 1997; 89:3727-34.
19. 19. Jansen PM, Boermeester MA, Fischer E, et al. Contribution of interleukin-1 to activation of coagulation and fibrinolysis, neutrophil degranulation, and the release of secretory-type phospholipase A2 in sepsis: studies in nonhuman primates after interleukin-1α administration and during lethal bacteremia. Blood 1995; 86:1027-34.
20. 20. Jansen PM, van Damme J, Put W, de Jong IW, Taylor FB Jr, Hack CE. Monocyte chemotactic protein 1 is released during lethal and sublethal bacteremia in baboons. J Infect Dis 1995; 171:1640-2.
21. 21. Tracey KJ, Fong Y, Hesse DG, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330: 662-4.
22. 22. Fong Y, Tracey KJ, Moldawer LL, et al. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1β and interleukin 6 appearance during lethal bacteremia. J Exp Med 1989; 170:1627-33.
23. 23. Fischer E, Marano MA, Van Zee KJ, et al. Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest 1992; 89:1551-7.
24. 24. van der Poll T, Büller HR, ten Cate H, et al. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990; 322:1622-7.
25. 25. van der Poll T, Jansen PM, van Zee KJ, et al. Tumor necrosis factor-α induces activation of coagulation and fibrinolysis in baboons through an exclusive effect on the p55 receptor. Blood 1996; 88:922-7.
26. 26. Ogilvie AC, Hack CE, Wagstaff J, et al. IL-1β does not cause neutrophil degranulation but does lead to IL-6, IL-8, and nitrite/nitrate release when used in patients with cancer. J Immunol 1996; 156:389-94.
27. 27. Ozmen L,Pericin M, Hakimi J, et al. Interleukin 12, interferon γ, and tumor necrosis factor α are the key cytokines of the generalized Shwartzman reaction. J Exp Med 1994; 180:907-15.
28. 28. Gazzinelli RT, Hieny S, Wynn TA, Wolf S, Sher A. Interleukin 12 is required for the T-lymphocyte independent induction of interferon-γ by an intracellular parasite and induces resistance in T-cell deficient hosts. Proc Natl Acad Sci USA 1993; 90:6115-9.
29. 29. Carson WE, Giri JG, Lindemann MJ, et al. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med 1994; 180:1395-403.
30. 30. Carson WE, Ross ME, Baiocchi RA, et al. Endogenous production of interleukin 15 by activated human monocytes is critical for optimal production of interferon-γ by natural killer cells in vitro. J Clin Invest 1995;96: 2578-82.
31. 31. Okamura H, Tsutsui H, Komatsu T, et al. Cloning of a new cytokine that induces IFN-γ production by T cells. Nature 1995; 378:88-91.
32. 32. Zhang T, Kawakami K, Qureshi MH, Okamura H, Kurimoto M, Saito A. Interleukin-12 (IL-12) and IL-18 synergistically induce the fungicidal activity of murine peritoneal exudate cells against Cryptococcus neoformans through production of gamma interferon by natural killer cells. Infect Immun 1997; 65:3594-9.
33. 33. Ahn HJ, Maruo S, Tomura M, et al. A mechanism underlying synergy between IL-12 and IFN-γ-inducing factor in enhanced production of IFN-γ. J Immunol 1997; 159:2125-31.
34. 34. Takeda K, Tsutsui H, Yoshimoto T, et al. Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity 1998; 8:383-90.
35. 35. Fantuzzi G, Puren AJ, Harding MW, Livingston DJ, Dinarello CA. Interleukin-18 regulation of interferon γ production and cell proliferation as shown in interleukin-1β-converting enzyme (caspase-1) deficient mice. Blood 1998; 91:2118-25.
36. + human blood mononuclear cells. J Clin Invest 1998; 101: 711-21.
37. 37. Robinson D, Shibuya K, Mui A, et al. IGIF does not drive Th1 development but synergizes with IL-12 for interferon-γ production and activates IRAK and NFκB. Immunity 1997; 7:571-81.
38. 38. Ohtsuki T, Micallef MJ, Kohno K, Tanimoto T, Ikeda M, Kurimoto M. Interleukin 18 enhances Fas ligand expression and induces apoptosis in Fas-expressing human myelomonocytic KG-1 cells. Anticancer Res 1997; 17:3253-8.
39. 39. Boring L, Gosling J, Chensue SW, et al. Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice. J Clin Invest 1997; 100:2552-61.
40. 40. Struyf S, Van Collie E, Paemen L, et al. Synergistic induction of MCP-1 and -2 by IL-1β and interferons in fibroblasts and epithelial cells. J Leukoc Biol 1998; 63:364-72.
41. 41. Luster AD, Ravetch JV. Biochemical characterization of a gamma interferon-inducible cytokine (IP-10). J Exp Med 1987; 166:1084-97.
42. 42. Trinchieri G. Interleukin-12 and interferon-γ. Do they always go together? Am J Pathol 1995; 147:1534-8.
43. 43. Atkins MB, Robertson MJ, Gordon M, et al. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res 1997; 3:409-17.